Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
Go back to Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)| TONIX PHARM HLDG (NASDAQ: TNXP) | Delayed: 10.59 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.59 | 52 Week High | $7.95 | |||
| Open | $10.59 | 52 Week Low | $0.40 | |||
| Day High | $10.59 | P/E | N/A | |||
| Day Low | $10.59 | EPS | $-5.33 | |||
| Volume | 808 | |||||
